How Cytodyme is Revolutionizing Cell & Gene Therapy Development!
Oceanside Current
Author: Sarai Garcia Editor: Irene Qin
Welcome to Oceanside Current, our biweekly newsletter where you can stay current on Oceanside Perspective news and announcements! Get first dibs on future content releases, event sign-ups, research projects, and product launches.
Welcome back to Oceanside Perspective's new series, "Purpose: Why Medicine?,” where we hear firsthand from the professionals shaping healthcare today! This week, we spotlight the inspiring journeys and unwavering commitment of Dennis White (CEO) and Tammy Ogden (CBO), Co-founders of Cytodyme, who are streamlining the development of cell and gene therapies!
"No one should have to choose between debt and death. They should always be choosing life." This powerful statement from Dennis (D.J.) encapsulates the driving force behind Cytodyme's mission to transform healthcare. In this inspiring conversation, hosted by Irene Qin, D.J. and Tammy share their personal journeys to entrepreneurship and how their pioneering software will increase accessibility to life-saving treatments.
As part of our dedicated O.P. community, you’re getting exclusive early access to this exciting new interview! Watch on Youtube! Or listen to it on the go with Oceanside Chat, available on all podcast platforms!
Message in a Bottle
We've learned a lot about D.J. and Tammy's experiences and dedication to their mission. Here are 4 key takeaways from their story!
📖 Purpose-Driven Entrepreneurship: At the heart of Cytodyme's mission lies the belief that financial constraints should never dictate people's access to life-saving medical care. D.J. and Tammy's personal experiences witnessing the gaps and obstacles in the system spurred their passion to create a better future for patients.
📊 The Promise of Transformative Outcomes: Cell and gene therapy represents a paradigm shift in medicine, offering significantly higher survival rates of around 80%, compared to traditional approaches at around 8%. However, these innovations remain out-of-reach to most patients due to unnecessary roadblocks, lack of scalability, and exorbitant development costs.
👩💼 Addressing Inefficiencies Systemically: Recognizing the slow, expensive, and complex nature of bringing cell and gene therapies to market, Cytodyme embarked on a mission to streamline the entire process, from lab bench to manufacturing to clinical trials.
⚡ Leveraging Technology for Accessibility: Cytodyme's main strategies involve integrating AI and other advanced technologies to help accelerate the development timeline. This focus on tech-driven innovation is crucial for reducing the steep costs and delivering effective treatments to patients faster.
Share your thoughts with us in the comments section or by sharing your response with Message in a Bottle!
Socials
As we continue to build up Oceanside Perspective, we want you to be a part of the journey! Stay up to date with our social media platforms: